A Phase I/II Study of LDE225 in Pediatric Patients With Recurrent or Refractory Medulloblastoma or Other Tumors Potentially Dependent on the Hedgehog-signaling Pathway and Adult Patients With Recurrent or Refractory Medulloblastoma
Phase of Trial: Phase I/II
Latest Information Update: 30 Sep 2017
At a glance
- Drugs Sonidegib (Primary)
- Indications Astrocytoma; Hepatoblastoma; Medulloblastoma; Neuroblastoma; Rhabdomyosarcoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 01 Mar 2016 Protocol amended as treatment arms changed from 1 to 5 as reported by ClinicalTrials.gov.
- 25 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 05 Oct 2014 Planned End Date changed from 1 Aug 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov.